See a virtual headache specialist in 1-2 days! Get HALF off your first month!

IT's BACK: TorqueGlide (with cannabinoids) is now in stock!

Migraine Book on Amazon

Evidence-Based Guide to Migraine Nutraceuticals and Herbal Options

Posted on August 04 2025, By: Cerebral Torque

← Back to Migraine Resource Hub
Stay in the Loop on the Latest in Migraine:

Migraine Nutraceuticals and Herbal Options

Evidence-based natural options for migraine prevention and treatment
August 2025
Quick Navigation
Overview Nutraceuticals Herbal Products Effectiveness ComparisonAdditional Resources

Overview

Natural approaches to migraine management offer options for patients seeking alternatives or additions to conventional treatments. This guide covers evidence-based nutraceuticals and herbal products that have shown promise in migraine prevention and treatment, based on the latest clinical research.

Note: If your supplement isn't listed here, the evidence, if any exists, is too low to recommend it. This includes common migraine supplements like B12. However, any actual deficiencies must be corrected as they absolutely contribute to migraine progression. Anything that disrupts homeostasis can fuel migraine disease.

Important

While these natural products can be effective, they should complement, not replace, comprehensive migraine care. Furthermore, "natural" does not mean safe. Always consult with your healthcare provider before starting any new treatment, especially if you're taking other medications.

Nutraceuticals

Nutritional supplements that include vitamins, minerals, and other compounds targeting specific metabolic pathways involved in migraine pathophysiology. Examples:

  • Riboflavin (Vitamin B2)
  • Magnesium
  • Coenzyme Q10
  • Alpha-lipoic acid
  • Vitamin D3

Herbal Products

Plant-based medicines with traditional use histories, now supported by modern clinical research. Examples:

  • Ginger (Zingiber officinale)
  • Menthol (Peppermint)
  • Feverfew (Tanacetum parthenium)
  • Butterbur (Petasites hybridus)
  • Lavender

Nutraceuticals for Migraine

Riboflavin (Vitamin B2)
Evidence-Based Dose 400 mg daily
Evidence Quality High
Time to Full Effect 3 months
Clinical Research Evidence

Multiple controlled trials demonstrate riboflavin's effectiveness. The landmark Schoenen et al. (1998) study showed 59% of patients achieved >50% reduction in migraine days versus only 15% with placebo. This represents strong evidence for riboflavin as a preventive treatment.

Key Study Results

The RCT by Schoenen et al. treated 55 patients with riboflavin 400 mg daily for 3 months. Results showed significant reductions in attack frequency, with excellent tolerability. Subsequent pediatric studies demonstrated similar efficacy, with one retrospective study showing >50% attack frequency reduction in 68.4% of children.

Mechanism of Action

Riboflavin is essential for mitochondrial energy production as a precursor to flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). Migraine patients often have impaired brain energy metabolism, and riboflavin supplementation helps restore normal cellular energy function through complexes I and II of the electron transport chain.

Combination Therapy Evidence

Studies combining riboflavin with magnesium and CoQ10 show mixed results. While individual components are effective, combinations don't always show additive benefits. The Gaul et al. study found 42.3% responders with combination therapy versus 24.6% with placebo, but results weren't statistically significant.

Safety Profile

Excellent safety record with no significant contraindications. May cause harmless yellow-orange urine coloration. No clinically relevant drug interactions at therapeutic doses. Safe in pregnancy and pediatric populations.

Magnesium
Therapeutic Dose 400-600 mg daily
Evidence Quality High
Primary Use Prevention
Response Time 2-3 months
Clinical Evidence

Several randomized controlled trials demonstrate magnesium's effectiveness in migraine prevention. Studies show significant reductions in attack frequency, particularly in patients with magnesium deficiency. Most clinical trials used magnesium oxide, though other forms may offer better tolerability.

Magnesium Forms Comparison

Magnesium Type Absorption GI Tolerance Research Evidence Notes
Magnesium Oxide Low (4%) Poor Most studied Used in most migraine trials; causes diarrhea
Magnesium Glycinate High Excellent Limited Chelated form; best tolerated; may promote sleep
Magnesium Citrate Moderate Fair Some studies Good compromise between absorption and cost
Magnesium Malate Good Good Limited May help with energy/fatigue; good for fibromyalgia
Magnesium Taurate Good Good Limited May benefit cardiovascular health; calming effect
Magnesium L-Threonate Excellent Good None for migraine Crosses blood-brain barrier best; expensive

Clinical Selection Guide

For evidence-based approach: Start with magnesium oxide (most studied) but expect GI side effects

For better tolerance: Magnesium glycinate or citrate offer better absorption and fewer side effects

For specific benefits: Glycinate for sleep, malate for energy, taurate for cardiovascular support

Dosing Strategy

Clinical Dosing Guidelines
  • Start low: Begin with 200 mg daily and increase gradually
  • Divide doses: Take 200 mg twice daily rather than 400 mg once
  • Take with food: Reduces GI irritation
  • Evening dosing: May help with sleep, especially glycinate
  • If switching forms: Adjust dose based on elemental magnesium content

Mechanism and Clinical Rationale

Magnesium modulates NMDA receptors, stabilizes neuronal membranes, and influences neurotransmitter release. It's involved in >300 enzymatic reactions, including energy metabolism and inflammation control. Magnesium deficiency is common in migraine patients and correction may normalize neuronal excitability.

Safety Considerations

Main side effect is diarrhea, particularly with oxide form. Use caution in patients with kidney disease. Monitor for interactions with antibiotics, bisphosphonates, and certain medications. Magnesium can enhance the effects of muscle relaxants and blood pressure medications.

Coenzyme Q10 (CoQ10)
Therapeutic Dose 100-300 mg daily
Evidence Quality Moderate
Special Population Pediatric patients
Research Evidence

Multiple studies showed CoQ10's effectiveness, particularly in pediatric populations. Pediatric studies by Hershey et al. found especially strong results in children with low baseline CoQ10 levels.

Pediatric Findings

Studies demonstrate that pediatric patients with frequent headaches and documented CoQ10 deficiency experience significant improvement. Open-label studies show >50% reduction in headache frequency in up to 65% of pediatric patients.

Adult Findings

Adult studies show more variable results. Effect sizes tend to be smaller in adults compared to pediatric populations, possibly due to age-related changes in CoQ10 metabolism.

Bioavailability Considerations

CoQ10 absorption varies significantly between individuals. Taking with dietary fats improves absorption. Ubiquinol (reduced form) may have better bioavailability than ubiquinone, though most migraine research used ubiquinone. Consider baseline CoQ10 levels in treatment decisions.

Safety Profile

Excellent safety record across all age groups. Minimal side effects reported. No significant drug interactions at therapeutic doses. May have mild anticoagulant effects - monitor INR if on warfarin.

Alpha-Lipoic Acid (ALA)
Evidence-Based Dose 600 mg daily
Evidence Quality Moderate
Special Indication Insulin resistance
Clinical Evidence

Magis et al. conducted a randomized, double-blind, placebo-controlled trial (43 patients) showing significant reduction in attack frequency, migraine days, and severity with 600 mg daily for 3 months. However, no significant difference in 50% responder rate compared to placebo.

Mechanism and Clinical Rationale

ALA serves as a cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase in the Krebs cycle (some of you may know it as the TCA cycle). It acts as a universal antioxidant, regenerating vitamins C and E, and glutathione. May be particularly beneficial in patients with metabolic dysfunction or insulin resistance.

Target Population

Studies suggest ALA may be most effective in patients with insulin resistance or metabolic syndrome. One study showed reduced serum lactate and vascular cell adhesion molecule-1 levels, indicating potential vascular benefits beyond migraine reduction.

Safety and Monitoring

Generally well tolerated. May cause GI upset in some patients.

Important: Can enhance insulin sensitivity - monitor blood glucose in diabetic patients. Avoid in patients with thiamine deficiency.

Vitamin D3
Optimal Dose 4000 IU daily
Evidence Quality Moderate
Target Population Vitamin D deficient
Clinical Research

Three RCTs have evaluated vitamin D3 in migraine prevention. Pediatric studies showed superior results with 4000 IU daily combined with topiramate: 75.9% achieved >50% headache reduction versus 36% with topiramate alone. Adult studies show benefits primarily in deficient patients.

Deficiency-Migraine Connection

Vitamin D deficiency is significantly more common in migraine patients compared to healthy controls. Studies demonstrate inverse correlation between 25(OH)D levels and migraine frequency. Correction of deficiency appears essential for therapeutic benefit.

Optimal Dosing Strategy

Higher doses (4000 IU daily) consistently show superior results compared to lower doses (2000 IU).

Safety and Monitoring

Check baseline 25(OH)D (vitamin D) levels before treatment. Monitor serum calcium with high-dose therapy. Contraindicated in hypercalcemia, sarcoidosis. Interactions with thiazide diuretics and digoxin.

Omega-3 Fatty Acids (EPA/DHA)
Effective Dose EPA 1.8g + DHA 1.2g daily
Evidence Quality Mixed Results
Treatment Period 3+ months
Research Summary

Network meta-analysis of 5 trials showed inconsistent results: 3 negative, 2 positive studies. One high-quality RCT (70 patients) found reduced migraine days with high-dose EPA/DHA. Lower doses (180-720 mg total) showed minimal benefits.

Dose-Response Relationship

Studies suggest a clear dose-response relationship. Effective studies used EPA 1.8 g plus DHA, while studies with lower total omega-3 content (<1g daily) generally showed no benefit. This indicates higher doses may be necessary for therapeutic effect.

Safety Profile

Excellent safety record. May cause mild GI upset or fishy aftertaste. Monitor bleeding parameters in patients on anticoagulants due to antiplatelet effects.

L-Carnitine
Combination Dose 3 g + CoQ10 30 mg daily
Evidence Quality Limited
Monotherapy Ineffective
Research Evidence

RCTs show no significant benefit for L-carnitine monotherapy. However, Hajihashemi et al. demonstrated positive effects when combined with CoQ10: reduced headache severity, frequency, and duration with decreased serum lactate levels in a double-blind RCT.

Clinical Application

Consider only in patients with documented carnitine deficiency or in combination with CoQ10. Case reports suggest benefit in carnitine deficiency-related migraine, but routine use isn't supported by current evidence.

Safety Profile

Generally well tolerated. May cause GI upset or fishy body odor. Consider testing carnitine levels before supplementation to identify deficient patients most likely to benefit.

Herbal Products for Migraine

Ginger (Zingiber officinale)
Acute Treatment Dose Varies (minimum 250 mg)
Evidence Quality High
Primary Use Acute Treatment
Onset of Action 30 minutes
Clinical Evidence

RCT by Maghbooli et al. demonstrated ginger 250 mg provided comparable efficacy to sumatriptan 50 mg with significantly fewer side effects. Study showed similar pain relief at 2 hours, though results should be interpreted cautiously due to methodological limitations.

Active Compounds and Mechanism

Ginger contains 6-gingerol, 8-gingerol, and 6-shogaol that inhibit prostaglandin E2 synthesis, have anti-inflammatory effects through 5-lipoxygenase inhibition, and modulate serotonin 5-HT3 receptors. May also affect CGRP pathways involved in migraine pathophysiology.

Clinical Application Protocol

Most effective when taken at first sign of migraine attack symptoms. Use standardized ginger powder rather than fresh ginger for consistent dosing. Can repeat after 2 hours if initial dose provides insufficient relief. Not effective for prophylaxis based on current evidence.

Safety and Contraindications

Excellent safety profile for acute use. Safe in pregnancy at food-level doses.

Caution: May enhance anticoagulant effects - avoid concurrent use with warfarin without medical supervision.

Topical Menthol
Application Topical Solution
Evidence Quality Moderate
Primary Use Acute Treatment
Onset 5-15 minutes
Clinical Evidence

Borhani Haghighi et al. conducted a randomized, double-blind, placebo-controlled crossover study showing menthol solution provided significant pain relief within 15 minutes. 50% of patients achieved meaningful pain reduction when applied to temples and forehead.

Mechanism and Application

Menthol activates TRPM8 (cold-sensing) receptors providing analgesic effects through counter-irritant mechanisms. Apply to temples, forehead, and neck using gentle circular motions. Effects typically last 2-4 hours and can be reapplied as needed.

Safety Notes

Generally safe for topical use. May cause skin irritation in sensitive individuals. Always test on small area first. Avoid contact with eyes and mucous membranes.

Curcumin (Turmeric Extract)
Effective Dose 500-600 mg daily
Evidence Quality Moderate
Primary Use Prevention
Time to Effect 8 weeks
Clinical Evidence

Double-blind RCT in Iranian women showed curcumin 500 mg twice daily significantly reduced migraine attack duration and severity compared to placebo over 8 weeks. Attack frequency showed a trend toward reduction. Serum CGRP levels were significantly decreased by curcumin treatment.

Mechanism of Action

Curcumin contains multiple active compounds including curcumin (77%), demethoxycurcumin (17%), and bisdemethoxycurcumin (6%). These compounds have anti-inflammatory effects through multiple pathways and may modulate CGRP levels involved in migraine pathophysiology.

Important Considerations

Studies used curcumin extract rather than whole turmeric. Curcumin has poor bioavailability when taken alone - combining with piperine (black pepper extract) or using specialized formulations improves absorption. Most research used standardized extracts containing 95% curcuminoids.

Safety Profile

Generally well tolerated with minimal side effects reported. May enhance effects of anticoagulant medications. Avoid in patients with gallstones or bile duct obstruction. Use caution with blood thinning medications.

Cinnamon (Cinnamomum verum)
Effective Dose 600 mg daily
Evidence Quality Moderate
Primary Use Prevention
Response Time 2-3 months
Clinical Evidence

Double-blind RCT with 43 Iranian adults showed cinnamon bark powder 600 mg daily significantly reduced attack frequency, duration, and severity compared to placebo. Signs of reduced inflammation were noted, including reduced serum IL-6 levels.

Active Compounds

Cinnamon contains cinnamaldehyde and phenylpropanoids with TRPV1 and TRPA1 agonist properties similar to ginger. These compounds provide anti-inflammatory effects and may help modulate pain pathways involved in migraine.

Safety Profile

Excellent safety record for Ceylon cinnamon (C. verum). Cassia cinnamon (C. cassia) contains higher coumarin levels and should be avoided with long-term use. True cinnamon is generally safe for extended use.

Capsaicin (Topical)
Application 0.025-0.075% cream
Evidence Quality Moderate
Primary Use Acute & Prevention
Onset Immediate to hours
Clinical Evidence

Multiple studies show capsaicin applied to temporal arteries, occipital arteries, and intranasally can provide significant pain relief. Italian study found 80% of subjects reported substantial headache pain relief within seconds of application, lasting several hours.

Mechanism and Application

Capsaicin works as a TRPV1 agonist, causing initial activation followed by desensitization of pain receptors. Apply small amounts to temples and back of neck. Intranasal application (professional setting) may be more effective but causes intense initial discomfort.

Safety Warnings

Critical: Wash hands thoroughly after application. Avoid eye contact completely. Start with lower concentrations (0.025%). Expect initial burning sensation. Not recommended for self-administered intranasal use due to intense pain.

Lavender (Lavandula angustifolia)
Application Essential oil inhalation
Evidence Quality Moderate
Primary Use Acute treatment
Onset 15 minutes
Clinical Evidence

Placebo-controlled trial showed lavender essential oil inhalation for 15 minutes significantly reduced headache severity in 47 Iranian adults. Participants reported notable improvement in nausea, vomiting, photophobia, and phonophobia.

Application Method

Place 2-3 drops of lavender essential oil on upper lip and inhale deeply, or use aromatherapy diffuser. For topical application, dilute with carrier oil (2-3 drops per teaspoon). Some patients benefit from inhaling directly from the bottle for 10-15 minutes.

Safety Profile

Good safety record for aromatherapy use. May cause skin irritation if applied undiluted. Generally safe in pregnancy at aromatherapy doses. Avoid internal use.

Butterbur (Petasites hybridus)
Historical Dose 75 mg twice daily
Evidence Quality High
Safety Concern Liver Hepatotoxicity
Current Status Not recommended
Efficacy Evidence

Multiple high-quality studies demonstrated butterbur's effectiveness. Lipton et al. showed butterbur extract (7.5 mg petasin twice daily) reduced migraine frequency up to 48% versus placebo. Despite strong efficacy evidence, serious safety concerns limit clinical use.

Critical Safety Warning - Do Not Use

Current Clinical Recommendation: Butterbur is no longer recommended by major headache societies despite strong efficacy evidence. Multiple cases of severe hepatotoxicity, including liver transplantation, have been reported even with "PA-free" products. Risk-benefit ratio is unfavorable for routine clinical use.

Historical Context

Butterbur was previously considered a first-line preventive treatment based on multiple positive RCTs. However, post-marketing surveillance revealed serious hepatotoxicity risk that outweighs therapeutic benefits, leading to withdrawal of recommendations.

Feverfew (Tanacetum parthenium)
Typical Dose 100-150 mg daily
Evidence Quality Mixed Results
Active Compound Parthenolide
Evidence Assessment

Multiple controlled trials show mixed results. Some studies using standardized extracts found significant reductions in attack frequency (up to 62% in combination studies), while others showed minimal benefit. Product standardization varies dramatically (parthenolide content 0.1-0.7%).

Recent Research Findings

A combination study with feverfew 100 mg, CoQ10 100 mg, and magnesium 112.5 mg daily showed 75% of patients achieved ≥50% reduction in headache days compared to baseline. However, isolated feverfew studies remain inconsistent.

Clinical Recommendation

Given inconsistent evidence as monotherapy, feverfew may be most effective when combined with other proven supplements like CoQ10 and magnesium. Ensure products are standardized to parthenolide content for consistency.

Effectiveness Comparison

This table compares the effectiveness and safety profiles of various natural migraine treatments based on available research evidence.

Treatment Evidence Quality Effectiveness Safety Primary Use Time to Effect
Riboflavin 400 mg High 50% reduction in responders Excellent Prevention 3 months
Magnesium 400-600 mg High Significant frequency reduction Good Prevention 2-3 months
Ginger 250 mg High Comparable to sumatriptan Excellent Acute treatment 30 minutes
CoQ10 100-300 mg Moderate Good in pediatric patients Excellent Prevention 2-3 months
Menthol (topical) Moderate 50% pain reduction Excellent Acute treatment 5-15 minutes
Curcumin 500 mg Moderate Reduced duration & severity Good Prevention 8 weeks
Cinnamon 600 mg Moderate Reduced frequency & severity Excellent Prevention 2-3 months
Capsaicin (topical) Moderate 80% report pain relief Fair Acute treatment Seconds
Lavender (inhaled) Moderate Reduced severity & symptoms Excellent Acute treatment 15 minutes
Alpha-lipoic acid Moderate Moderate frequency reduction Good Prevention 2-3 months
Vitamin D3 Moderate Good if deficient Excellent Prevention 2-4 months
Butterbur extract High Up to 48% reduction Poor Prevention 2-3 months
Feverfew Low Mixed results (better in combinations) Good Prevention Variable

Special Population Guidelines

Pregnancy and Lactation

Safe Options:

  • Ginger (food-level doses) - safe for nausea
  • Magnesium glycinate - generally safe
  • Vitamin D3 - if deficient (≤4000 IU)

Absolutely Avoid:

  • Feverfew - uterine stimulant properties
  • Butterbur - hepatotoxicity risk
  • High-dose supplements without indication

Pediatric Populations

Good Options:

  • CoQ10 (100-300 mg) - best pediatric evidence
  • Riboflavin (200-400 mg) - dose by weight
  • Magnesium (200-400 mg) - excellent safety

Avoid:

  • Butterbur - serious safety concerns
  • High-dose fat-soluble vitamins
  • Herbal combinations

Clinical Implementation

Getting Started

  1. Consult your healthcare provider - Discuss which options might be best for your specific situation
  2. Start with single agents - Don't begin multiple supplements simultaneously
  3. Keep a migraine diary - Track frequency, severity, and response to treatments
  4. Be patient - Most preventive treatments take 2-3 months to show full effects

Combination Strategies

Some patients benefit from combining multiple natural approaches. Research supports certain combinations:

Evidence-Based Combinations
  • Riboflavin + Magnesium: Synergistic mitochondrial effects, different mechanisms
  • CoQ10 + Riboflavin: Enhanced electron transport chain function
  • Vitamin D3 + Magnesium: Complementary anti-inflammatory mechanisms
  • Ginger + Topical Menthol: Dual-pathway acute treatment approach

Remember

Natural approaches can be valuable additions to migraine management, but they work best as part of a comprehensive treatment plan that may include lifestyle modifications, stress management, and appropriate medical care. The goal is to find the safest and most effective combination of treatments for your individual needs.

Disclaimer

This guide is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always consult qualified healthcare providers before starting, stopping, or modifying any treatment regimen.

References

  1. Schoenen, J., Jacquy, J., & Lenaerts, M. (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology, 50(2), 466–470.
  2. Condó, M., Posar, A., Arbizzani, A., & Parmeggiani, A. (2009). Riboflavin prophylaxis in pediatric and adolescent migraine. The Journal of Headache and Pain, 10(5), 361–365.
  3. Boehnke, C., Reuter, U., Flach, U., Schuh-Hofer, S., Einhäupl, K. M., & Arnold, G. (2004). High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. European Journal of Neurology, 11(7), 475–477.
  4. Schoenen, J., Lenaerts, M., & Bastings, E. (1994). High-dose riboflavin as a prophylactic treatment of migraine: Results of an open pilot study. Cephalalgia, 14(4), 328–329.
  5. Peikert, A., Wilimzig, C., & Köhne-Volland, R. (1996). Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia, 16(4), 257–263.
  6. Facchinetti, F., Sances, G., Borella, P., Genazzani, A. R., & Nappi, G. (1991). Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache, 31(5), 298–301.
  7. Köseoglu, E., Talaslioglu, A., Gönül, A. S., & Kula, M. (2008). The effects of magnesium prophylaxis in migraine without aura. Magnesium Research, 21(2), 101–108.
  8. Wang, F., Van Den Eeden, S. K., Ackerson, L. M., Salk, S. E., Reince, R. H., & Elin, R. J. (2003). Oral magnesium oxide prophylaxis of frequent migrainous headache in children: A randomized, double-blind, placebo-controlled trial. Headache, 43(6), 601–610.
  9. Rozen, T. D., Oshinsky, M. L., Gebeline, C. A., Bradley, K. C., Young, W. B., Shechter, A. L., & Silberstein, S. D. (2002). Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia, 22(2), 137–141.
  10. Sándor, P. S., Di Clemente, L., Coppola, G., Saenger, U., Fumal, A., Magis, D., Seidel, L., Agosti, R. M., & Schoenen, J. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology, 64(4), 713–715.
  11. Hershey, A. D., Powers, S. W., Vockell, A. L., LeCates, S. L., Ellinor, P. L., Segers, A., Burdine, D., Manning, P., & Kabbouche, M. A. (2007). Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache, 47(1), 73–80.
  12. Slater, S. K., Nelson, T. D., Kabbouche, M. A., LeCates, S. L., Horn, P., Segers, A., Manning, P., Powers, S. W., & Hershey, A. D. (2011). A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia, 31(8), 897–905.
  13. Magis, D., Ambrosini, A., Sándor, P., Jacquy, J., Laloux, P., & Schoenen, J. (2007). A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache, 47(1), 52–57.
  14. Cavestro, C., Bedogni, G., Molinari, F., Mandrino, S., Rota, E., & Frigeri, M. C. (2018). Alpha-lipoic acid shows promise to improve migraine in patients with insulin resistance: A 6-month exploratory study. Journal of Medicinal Food, 21(3), 269–273.
  15. Ghorbani, Z., Togha, M., Rafiee, P., Ahmedi, Z. S., Rasekh Magham, R., Djalali, M., Shahemi, S., Martami, F., Zareei, M., & Razeghi Jahromi, S. (2020). Vitamin D in migraine headache: a comprehensive review on literature. Neurological Sciences, 41(11), 3141–3151.
  16. Fallah, R., Saraf Yazd, Z., & Soltaniyard, S. M. (2020). Efficacy of topiramate alone or in combination with vitamin D3 in the prophylaxis of pediatric migraine: A randomized clinical trial. Iranian Journal of Child Neurology, 14(4), 77–86.
  17. Elmala, S., Suliman, Al-Shokary, H. A., Ibrahim, A. H., Kamal, A. O., Elhorbany, N. M., Nasef, K. A., & El Din Fathallah, M. G. (2022). The impact of vitamin D3 supplementation to topiramate therapy on pediatric migraine prophylaxis. Journal of Child Neurology, 37(1), 52–62.
  18. Lea, R., Colson, N., Quinlan, S., Macmillan, J., & Griffiths, L. (2009). The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenetics and Genomics, 19(6), 422–428.
  19. Menon, S., Nasir, B., Avgan, N., Ghassabian, S., Oliver, C., Lea, R., Smith, M., & Griffiths, L. (2016). The effect of 1 mg folic acid supplementation on clinical outcomes in female migraine with aura patients. The Journal of Headache and Pain, 17(1), 60.
  20. Sadeghvand, S., Ranjzad, M., Shah, P., Soltani, S., Kholedari, H., Rahi Khamneh, Z., Golchinifar, Z., & Rasisi, S. (2023). The effects of vitamin B-complex supplementation on serum homocysteine levels and migraine severity in children. Iranian Journal of Child Neurology, 17(3), 141–153.
  21. Maghbooli, M., Golipour, F., Moghimi Esfandabadi, A., & Yousefi, M. (2014). Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytotherapy Research, 28(3), 412–415.
  22. Martins, L. B., Rodrigues, A. M. D. S., Rodrigues, D. F., dos Santos, L. C., Teixeira, A. L., Ferreira, A. V. M. (2019). Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) addition in migraine acute treatment. Cephalalgia, 39(1), 68–76.
  23. Martins, L. B., Rodrigues, A. M. D. S., Monteze, N. M., Thacs, J. R. B., Amaral, M. H. A., Gómez, R. S., Teixeira, A. L., Ferreira, A. V. M. (2020). Natural ginger (Zingiber officinale Rose.) in the prophylactic treatment of migraine. Cephalalgia, 40(10), 1033–1041.
  24. Fusco, B. M., Barzoi, G., Agrò, F. (2003). Repeated intranasal capsaicin applications to treat chronic migraine. British Journal of Anaesthesia, 90(6), 812.
  25. Aroni, V., Campbell, J. N., & Chung, M. K. (2021). Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain. Pharmacology & Therapeutics, 220, 107743.
  26. Chung, M. K., & Campbell, J. N. (2016). Use of capsaicin to treat pain: Mechanistic and therapeutic considerations. Pharmaceuticals, 9(4), 66.
  27. Borhani Haghighi, A., Motazedian, S., Rezaii, R., Mohammadi, F., Salarian, L., Pourmokhtari, M., Khodaei, S., Vossoughi, M., Miri, R. (2010). Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: A randomised, double-blind, placebo-controlled, crossover study. International Journal of Clinical Practice, 64(4), 451–456.
  28. Sasannejad, P., Saeedi, M., Shoeibi, A., Gorji, A., Abbasi, M., Foroughipour, M. (2012). Lavender essential oil in the treatment of migraine headache: A placebo-controlled clinical trial. European Neurology, 67(5), 288–291.
  29. Ernst, E., & Pittler, M. H. (2000). The efficacy and safety of feverfew (Tanacetum parthenium L.): An update of a systematic review. Public Health Nutrition, 3(4A), 509–514.
  30. Diener, H. C., Pfaffenrath, V., Schnitker, J., Friede, M., & Henneicke-Von Zepelin, H. H. (2005). Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia, 25(11), 1031–1041.
  31. Pfaffenrath, V., Wessely, P., Meyer, C., Isler, H. R., Evers, S., Grotemeyer, K. H., Taneri, Z., Soyka, D., Göbel, H., & Fischer, M. (2002). Magnesium in the prophylaxis of migraine—a double-blind placebo-controlled study. Cephalalgia, 16(6), 436–440.
  32. Lipton, R. B., Göbel, H., Einhäupl, K. M., Wilks, K., & Mauskop, A. (2004). Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology, 63(12), 2240–2244.
  33. Grossmann, M., & Schmidramsl, H. (2001). An extract of Petasites hybridus is effective in the prophylaxis of migraine. Alternative Medicine Review, 6(3), 303–310.
  34. Agosti, R., Duke, R. K., Chrubasik, J. E., & Chrubasik, S. (2006). Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: A systematic review. Phytomedicine, 13(9-10), 743–746.
  35. Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018). Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. The Journal of Headache and Pain, 19(1), 37.
  36. Schuster, N., Wallace, M., Muse, D., Marcotte, T., Lee, E., Liu, L., Sexton, M. (2024). Vaporized cannabis versus placebo for acute migraine: A randomized controlled trial (S2.010). Neurology, 102(17), S2.010.
  37. Kamali, A., Ramezani, S., Kamali, F., Kamali, M., Mehrabani, M., Jahani, Y., Tajadini, H. (2018). Efficacy of combination of Viola odorata, Rosa damascena and Coriandrum sativum in prevention of migraine attacks: A randomized, double blind, placebo-controlled clinical trial. Electronic Physician, 10(3), 6430–6438.
  38. Guilbot, A., Bangratz, M., Ait Abdellah, S., & Lucas, C. (2017). A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: A prospective observational study. BMC Complementary and Alternative Medicine, 17(1), 433.
  39. Hajihashemi, P., Askari, G., Khorvash, F., Reza Maracy, M., & Nourian, M. (2019). The effects of concurrent coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Cephalalgia, 39(5), 648–654.
  40. Gross, E. C., Lisicki, M., Fischer, D., Sándor, P. S., & Schoenen, J. (2019). The metabolic face of migraine — from pathophysiology to treatment. Nature Reviews Neurology, 15(11), 627–643.
  41. Thompson, D. F., & Saluja, H. S. (2017). Prophylaxis of migraine headaches with riboflavin: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 42(4), 394–403.
  42. Teigen, L., & Boes, C. J. (2015). An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia, 35(10), 912–922.
  43. Pradalier, A., et al. (2001). Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: A double-blind study versus placebo. Cephalalgia, 21(8), 818–822.
  44. Tseng, P. T., Yang, C. P., Su, J., Su, K. P., Wu, Y. C., Tu, Y. K., Lin, P. Y. (2024). High dosage omega-3 fatty acids outperform existing pharmacological options for migraine prevention: A network meta-analysis of 5 trials. Advances in Nutrition, 15(2), 100163.
  45. Rezaie, A., Askari, G., Khorvash, F., Tarrahi, M.J., Amani, R. (2021). Effects of curcumin supplementation on clinical features and inflammation. International Journal of Preventive Medicine 12 (1). https://doi.org/10.4103/ijpvm.IJPVM-405-20.
  46. Zareie, A., Sahebkar, A., Khorvash, F., Bagherniya, M., Hasanzadeh, A., Askari, G. (2020). Effect of curcumin on migraine attacks and inflammatory markers: A randomized double-blind placebo-controlled trial. Phytotherapy Research 34 (11), 2945–2952.

MigraineScience Blog

Join Our Community